Phase II Anetumab Ravtansine as 2nd Line Treatment for Malignant Pleural Mesothelioma (MPM) - Full Text View

Purpose

The main purpose of the 15743 study is to assess efficacy and safety of anetumab ravtansine versus vinorelbine in progression free survival in patients with stage IV mesothelin overexpressing malignant pleural mesothelioma (MPM).

210 eligible patients will be randomized to receive either anetumab ravtansine every three weeks or weekly vinorelbine.

Treatment will continue until centrally confirmed disease progression (PD) or until another criterion is met for withdrawal from the study. Patients will enter follow up phase to capture safety and endpoint data as required.

Efficacy will be measured by evaluating progression free survival from randomization. Radiological tumor assessments will be performed at defined time points until the patient's disease progresses.

Blood samples will be collected for safety, pharmacokinetic and biomarker analysis. Archival or fresh biopsy tissue may also be collected for central pathology review and biomarkers.

Condition	Intervention	Phase
Mesothelioma	Drug: Anetumab ravtansine (BAY 94-9343) Drug: Vinorelbine	Phase 2


Study Type:	Interventional
Study Design:	Allocation: Randomized Intervention Model: Parallel Assignment Masking: No masking Primary Purpose: Treatment
Official Title:	A Randomized, Open-label, Active-controlled, Phase II Study of Intravenous Anetumab Ravtansine (BAY 94-9343) or Vinorelbine in Patients With Advanced or Metastatic Malignant Pleural Mesothelioma Overexpressing Mesothelin and Progressed on First Line Platinum/Pemetrexed-based Chemotherapy

Resource links provided by NLM:

MedlinePlus related topics: Mesothelioma

Drug Information available for: Vinorelbine Vinorelbine tartrate

Genetic and Rare Diseases Information Center resources: Malignant Mesothelioma

U.S. FDA Resources

Further study details as provided by Bayer:

Primary Outcome Measures:

Progression Free Survival [ Time Frame: Approx. 22 months ]
Defined as time from randomization until disease progression or death. Patients not experiencing death or progression will be censored at the last tumor assessment.

Secondary Outcome Measures:

Overall survival (OS) [ Time Frame: Approx. 42 months ]
Defined as time from randomization until death from any cause. Patients lost to follow-up or alive at the time of analysis will be censored at the last known alive date.
Patient-reported outcomes (PROs) [ Time Frame: Approx. 22 months ]
PROs: Time to worsening of symptoms characteristic of mesothelioma, time to worsening of pain, time to improvement of symptoms characteristic of mesothelioma and time to improvement of pain. Symptoms will be assessed using the MD Anderson Symptom Inventory-Malignant Pleural Mesothelioma (MDASI-MPM) and the Lung Cancer Symptom Scale-Mesothelioma (LCSS-Meso).
Objective response rate (ORR) [ Time Frame: Approx. 22 months ]
A patient is a responder if the patient has a confirmed tumor response on-study of (complete response) CR or PR, as determined by the central radiological reviewer per Modified Response Evaluation Criteria in Solid Tumors (mRECIST) criteria for MPM. The ORR in each arm is the number of responders divided by the number of randomized patients.
Duration of response (DOR) [ Time Frame: Approx. 42 months ]
Defined as proportion of patients achieving CR, PR, or (Stable disease) SD per mRECIST criteria, as determined by the central radiological reviewer.
Number of participants with treatment emergent adverse events as a measure of safety and tolerability [ Time Frame: Approx. 22 months ]
Number of participants with serious adverse events as a measure of safety and tolerability [ Time Frame: Approx. 22 months ]
Disease control rate (DCR) [ Time Frame: Approx. 22 months ]
Defined as proportion of patients achieving CR, PR, or (Stable disease) SD per mRECIST criteria, as determined by the central radiological reviewer.
Durable Response Rate (DRR) [ Time Frame: Approx. 42 months ]
Defined in responders as a responder with a duration of response of 180 days or more as determined by the central radiological reviewer.


Enrollment:	248
Actual Study Start Date:	December 3, 2015
Estimated Study Completion Date:	July 29, 2019
Estimated Primary Completion Date:	June 15, 2017 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
Experimental: BAY 94-9343 Drug Anetumab ravtansine given Intravenously (IV)	Drug: Anetumab ravtansine (BAY 94-9343) Starting dose: 6.5 mg/kg administered as IV infusion over 1 h every 3 weeks until disease progression or treatment withdrawal for any reason. Dose reductions are permitted.
Active Comparator: Vinorelbine Drug Vinorelbine given Intravenously	Drug: Vinorelbine Starting dose: 30mg/m² administered as an IV infusion over 6 to 10 min every week until disease progression or treatment withdrawal for any reason. Dose reductions are permitted per standard practise.

Eligibility


Ages Eligible for Study:	18 Years and older (Adult, Senior)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Histological documentation of malignant pleural mesothelioma (MPM) overexpressing mesothelin
Unresectable locally advanced or metastatic MPM after locally confirmed progression on 1st line treatment with platinum in combination with pemetrexed.
Patients must have measurable disease
Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 or 1
Life expectancy of at least 3 months.
Adequate bone marrow, liver and renal function
Left ventricular ejection fraction (LVEF) ≥ 50% or the lower limit of normal (LLN) according to local institution ranges of normality.

Exclusion Criteria:

More than 1 previous systemic anti-cancer therapy line
Patients with corneal epitheliopathy or any eye disorder that may predispose the patients to this condition at the discretion of the ophthalmologist.
Brain metastases, meningeal tumours or other metastases in the central nervous system
Evidence of history of bleeding diathesis.
Ongoing or active infection (bacterial, fungal, or viral) of National Cancer Institute's Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 4.03 Grade > 2.
Pre-existing cardiac conditions

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT02610140

Show 99 Study Locations

Sponsors and Collaborators

Bayer

ImmunoGen and MorphoSys

Investigators


Study Director:	Bayer Study Director	Bayer

More Information

Additional Information:

Click here and search for drug information provided by the FDA. This link exits the ClinicalTrials.gov site

Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product. This link exits the ClinicalTrials.gov site


Responsible Party:	Bayer
ClinicalTrials.gov Identifier:	NCT02610140 History of Changes
Other Study ID Numbers:	15743 2012-003650-88 ( EudraCT Number )
Study First Received:	November 9, 2015
Last Updated:	May 15, 2017


Studies a U.S. FDA-regulated Drug Product:		Yes
Studies a U.S. FDA-regulated Device Product:		No

Additional relevant MeSH terms:


Mesothelioma Adenoma Neoplasms, Glandular and Epithelial Neoplasms by Histologic Type Neoplasms Neoplasms, Mesothelial Maytansine Vinorelbine Vinblastine	Immunoconjugates Antineoplastic Agents, Phytogenic Antineoplastic Agents Tubulin Modulators Antimitotic Agents Mitosis Modulators Molecular Mechanisms of Pharmacological Action Immunologic Factors Physiological Effects of Drugs

ClinicalTrials.gov processed this record on June 22, 2017